Home | Site Index | Contact | Disclaimer     
 

 

Approved for Marketing

Elestrin™
low dose estradiol ATD™ gel launched June 2007

Medi-Jector VISION®

needle-free device for use with insulin

ZomaJet® 2 Vision
marketed by Ferring for hGH in Europe

Twin-Jector® EZ II
marketed by JCR Pharmaceuticals Co. Ltd. for hGH in Japan

SciTojet2™
marketed by SciGen Ltd. for hGH in Asia

Ibuprofen gel
in 11 countries

 

   

BUSINESS DEVELOPMENT

 

Licensing

 

In our partnerships, Antares shares the desire to bring novel therapeutics to patients on a global basis. Antares delivers what is valued most in a partner: validated expertise and flexibility to move products successfully through development, experience to bring products to patients faster, global resources essential to product success, and the commitment Antares shares to dramatically improve quality of life for patients. We appreciate your consideration of Antares as your partner, and assure you that your opportunity will receive our full attention.
 

 

Development and Commercialization Partnerships

 

Antares is currently seeking licensing partners for its mid and late stage development product candidates, as well as opportunites to utilize its proprietary platforms with partners’ pharmaceutical ingredients. Non-confidential summaries of our products and platforms are available upon request.

To find out more about businesses development opportunities with Antares, please contact:

 

Pharma Group

 

James E. Hattersley

 

VP, Corporate Business Development

Tel.: +1 (609) 359 3033

 

jhattersley@antarespharma.com

 

  Device Group

 

Michael L. Kasprick

 

VP Business Development

Tel.: +1 (763) 475 7769

 

mkasprick@antarespharma.com

 

 

 

 

 

 
 

Navigation Main:  Company Overview  |  Corporate  |  Investor Relations  |  Platforms  |   Products / Pipeline  |  Business Development

 

 © 2007 Antares Pharma Inc. - All rights reserved.